Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 453

1.

Design and conduct of early clinical studies of immunotherapy agent combinations: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.

Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G; task force on Methodology for the Development of Innovative Cancer Therapies.

Ann Oncol. 2018 Sep 10. doi: 10.1093/annonc/mdy398. [Epub ahead of print]

PMID:
30202892
2.

Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference.

Dyer A, Baugh R, Chia SL, Frost S, Iris, Jacobus EJ, Khalique H, Pokrovska TD, Scott EM, Taverner WK, Seymour LW, Lei J.

Cancer Gene Ther. 2018 Sep 4. doi: 10.1038/s41417-018-0042-1. [Epub ahead of print]

PMID:
30177818
3.

Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.

Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, Olaussen KA, Fulton R, Sakashita S, McLeer-Florin A, Ding K, Le Teuff G, Shepherd FA, Pignon JP, Graziano SL, Kratzke R, Soria JC, Seymour L, Govindan R, Michiels S.

J Clin Oncol. 2018 Aug 14:JCO2018781963. doi: 10.1200/JCO.2018.78.1963. [Epub ahead of print]

PMID:
30106638
4.

Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer.

Rotolo F, Zhu CQ, Brambilla E, Graziano SL, Olaussen K, Le-Chevalier T, Pignon JP, Kratzke R, Soria JC, Shepherd FA, Seymour L, Michiels S, Tsao MS.

Transl Lung Cancer Res. 2018 Jun;7(3):416-427. doi: 10.21037/tlcr.2018.05.01.

5.

Identity and Seasonal Abundance of Beneficial Arthropods Associated with Big Sagebrush (Artemisia tridentata) in Central Washington State, USA.

James DG, Seymour L, Lauby G, Buckley K.

Insects. 2018 Jun 28;9(3). pii: E76. doi: 10.3390/insects9030076.

6.

An unusual case of myeloma.

Tate C, McKinley M, Seymour L.

Pathology. 2018 Aug;50(5):581-584. doi: 10.1016/j.pathol.2018.01.011. Epub 2018 Jun 18. No abstract available.

PMID:
29921449
7.

Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.

Lei J, Jacobus EJ, Taverner WK, Fisher KD, Hemmi S, West K, Slater L, Lilley F, Brown A, Champion B, Duffy MR, Seymour LW.

J Immunother Cancer. 2018 Jun 13;6(1):55. doi: 10.1186/s40425-018-0350-x.

8.

Group A Streptococcus M1T1 Intracellular Infection of Primary Tonsil Epithelial Cells Dampens Levels of Secreted IL-8 Through the Action of SpyCEP.

Soderholm AT, Barnett TC, Korn O, Rivera-Hernandez T, Seymour LM, Schulz BL, Nizet V, Wells CA, Sweet MJ, Walker MJ.

Front Cell Infect Microbiol. 2018 May 17;8:160. doi: 10.3389/fcimb.2018.00160. eCollection 2018.

9.

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.

Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C, Kuruvilla S, Keith BD, Torri V, Blais N, Hao D, Korpanty GJ, Goss G, Melosky BL, Mates M, Leighl N, Ayoub JP, Sederias J, Feilotter H, Seymour L, Laurie SA.

Lung Cancer. 2018 Jun;120:142-148. doi: 10.1016/j.lungcan.2018.03.005. Epub 2018 Mar 9.

PMID:
29748010
10.

A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.

Jonker DJ, Tang PA, Kennecke H, Welch SA, Cripps MC, Asmis T, Chalchal H, Tomiak A, Lim H, Ko YJ, Chen EX, Alcindor T, Goffin JR, Korpanty GJ, Feilotter H, Tsao MS, Theis A, Tu D, Seymour L.

Clin Colorectal Cancer. 2018 Sep;17(3):231-239.e7. doi: 10.1016/j.clcc.2018.03.001. Epub 2018 Mar 8.

PMID:
29653857
11.

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209.

Eigl BJ, Chi K, Tu D, Hotte SJ, Winquist E, Booth CM, Canil C, Potvin K, Gregg R, North S, Zulfiqar M, Ellard S, Ruether JD, Le L, Kakumanu AS, Salim M, Allan AL, Feilotter H, Theis A, Seymour L.

Oncotarget. 2018 Jan 17;9(8):8155-8164. doi: 10.18632/oncotarget.24263. eCollection 2018 Jan 30.

12.

Phenotyping acute and chronic atopic dermatitis-like lesions in Stat6VT mice identifies a role for IL-33 in disease pathogenesis.

DaSilva-Arnold SC, Thyagarajan A, Seymour LJ, Yi Q, Bradish JR, Al-Hassani M, Zhou H, Perdue NJ, Nemeth V, Krbanjevic A, Serezani APM, Olson MR, Spandau DF, Travers JB, Kaplan MH, Turner MJ.

Arch Dermatol Res. 2018 Apr;310(3):197-207. doi: 10.1007/s00403-018-1807-y. Epub 2018 Jan 24.

PMID:
29368135
13.

Clinical and molecular categorization of progressive, adult-onset cutaneous mastocytosis.

Tate C, Tang F, Lane SW, Seymour L.

JAAD Case Rep. 2017 Dec 18;4(1):30-32. doi: 10.1016/j.jdcr.2017.09.038. eCollection 2018 Jan. No abstract available.

14.

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.

Leighl NB, Tsao MS, Liu G, Tu D, Ho C, Shepherd FA, Murray N, Goffin JR, Nicholas G, Sakashita S, Chen Z, Kim L, Powers J, Seymour L, Goss G, Bradbury PA.

Oncotarget. 2017 Jun 28;8(41):69651-69662. doi: 10.18632/oncotarget.18753. eCollection 2017 Sep 19.

15.

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, Panasci L, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L.

Breast Cancer Res Treat. 2018 Jan;167(2):485-493. doi: 10.1007/s10549-017-4538-4. Epub 2017 Oct 13.

PMID:
29027598
16.

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.

Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, Boni V, Blanc C, Seymour L, Beadle J, Alvis S, Champion B, Calvo E, Fisher K.

J Immunother Cancer. 2017 Sep 19;5(1):71. doi: 10.1186/s40425-017-0277-7.

17.

Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.

Scott EM, Duffy MR, Freedman JD, Fisher KD, Seymour LW.

Macromol Biosci. 2018 Jan;18(1). doi: 10.1002/mabi.201700187. Epub 2017 Sep 13. Review.

PMID:
28902983
18.

Making Oncolytic Virotherapy a Clinical Reality: The European Contribution.

Duffy MR, Fisher KD, Seymour LW.

Hum Gene Ther. 2017 Nov;28(11):1033-1046. doi: 10.1089/hum.2017.112. Epub 2017 Aug 1. Review.

PMID:
28793793
19.

Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.

O'Cathail SM, Pokrovska TD, Maughan TS, Fisher KD, Seymour LW, Hawkins MA.

Front Oncol. 2017 Jul 24;7:153. doi: 10.3389/fonc.2017.00153. eCollection 2017. Review.

20.

Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.

Freedman JD, Hagel J, Scott EM, Psallidas I, Gupta A, Spiers L, Miller P, Kanellakis N, Ashfield R, Fisher KD, Duffy MR, Seymour LW.

EMBO Mol Med. 2017 Aug;9(8):1067-1087. doi: 10.15252/emmm.201707567.

21.

Anti-Inflammatory Activity and Structure-Activity Relationships of Brominated Indoles from a Marine Mollusc.

Ahmad TB, Rudd D, Smith J, Kotiw M, Mouatt P, Seymour LM, Liu L, Benkendorff K.

Mar Drugs. 2017 May 6;15(5). pii: E133. doi: 10.3390/md15050133.

22.

Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus.

Illingworth S, Di Y, Bauzon M, Lei J, Duffy MR, Alvis S, Champion B, Lieber A, Hermiston T, Seymour LW, Beadle J, Fisher K.

Mol Ther Oncolytics. 2017 Mar 29;5:62-74. doi: 10.1016/j.omto.2017.03.003. eCollection 2017 Jun 16.

23.

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.

Shepherd FA, Lacas B, Le Teuff G, Hainaut P, Jänne PA, Pignon JP, Le Chevalier T, Seymour L, Douillard JY, Graziano S, Brambilla E, Pirker R, Filipits M, Kratzke R, Soria JC, Tsao MS; LACE-Bio Collaborative Group.

J Clin Oncol. 2017 Jun 20;35(18):2018-2027. doi: 10.1200/JCO.2016.71.2893. Epub 2017 Apr 28.

24.

OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution.

Kuhn I, Bauzon M, Green N, Seymour L, Fisher K, Hermiston T.

Mol Ther Oncolytics. 2016 Dec 14;4:55-66. doi: 10.1016/j.omto.2016.12.001. eCollection 2017 Mar 17.

25.

Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators.

Dyer A, Di Y, Calderon H, Illingworth S, Kueberuwa G, Tedcastle A, Jakeman P, Chia SL, Brown A, Silva MA, Barlow D, Beadle J, Hermiston T, Ferguson DJ, Champion B, Fisher KD, Seymour LW.

Mol Ther Oncolytics. 2016 Dec 10;4:18-30. doi: 10.1016/j.omto.2016.11.003. eCollection 2017 Mar 17.

26.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EG; RECIST working group.

Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review.

27.

Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer.

Chia SL, Lei J, Ferguson DJP, Dyer A, Fisher KD, Seymour LW.

Virology. 2017 May;505:162-171. doi: 10.1016/j.virol.2017.02.011. Epub 2017 Mar 3.

28.

PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.

Tsao MS, Le Teuff G, Shepherd FA, Landais C, Hainaut P, Filipits M, Pirker R, Le Chevalier T, Graziano S, Kratze R, Soria JC, Pignon JP, Seymour L, Brambilla E.

Ann Oncol. 2017 Apr 1;28(4):882-889. doi: 10.1093/annonc/mdx003.

29.

RECIST - learning from the past to build the future.

Litière S, Collette S, de Vries EG, Seymour L, Bogaerts J.

Nat Rev Clin Oncol. 2017 Mar;14(3):187-192. doi: 10.1038/nrclinonc.2016.195. Epub 2016 Dec 20. Review.

PMID:
27995946
30.

A Rapid-Response Humoral Vaccine Platform Exploiting Pre-Existing Non-Cognate Populations of Anti-Vaccine or Anti-Viral CD4+ T Helper Cells to Confirm B Cell Activation.

Hills T, Jakeman PG, Carlisle RC, Klenerman P, Seymour LW, Cawood R.

PLoS One. 2016 Nov 18;11(11):e0166383. doi: 10.1371/journal.pone.0166383. eCollection 2016.

31.

BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.

Liu G, Cuffe S, Liang S, Azad AK, Cheng L, Brhane Y, Qiu X, Cescon DW, Bruce J, Chen Z, Cheng D, Patel D, Tse BC, Laurie SA, Goss G, Leighl NB, Hung R, Bradbury PA, Seymour L, Shepherd FA, Tsao MS, Chen BE, Xu W, Reisman DN.

Clin Cancer Res. 2017 May 15;23(10):2460-2470. doi: 10.1158/1078-0432.CCR-16-1640. Epub 2016 Nov 8.

32.

Increased Th2 activity and diminished skin barrier function cooperate in allergic skin inflammation.

Sehra S, Krishnamurthy P, Koh B, Zhou HM, Seymour L, Akhtar N, Travers JB, Turner MJ, Kaplan MH.

Eur J Immunol. 2016 Nov;46(11):2609-2613. doi: 10.1002/eji.201646421. Epub 2016 Aug 29.

33.

Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant.

Francica JR, Lynn GM, Laga R, Joyce MG, Ruckwardt TJ, Morabito KM, Chen M, Chaudhuri R, Zhang B, Sastry M, Druz A, Ko K, Choe M, Pechar M, Georgiev IS, Kueltzo LA, Seymour LW, Mascola JR, Kwong PD, Graham BS, Seder RA.

Bioconjug Chem. 2016 Oct 19;27(10):2372-2385. Epub 2016 Sep 22.

PMID:
27583777
34.

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.

Seftel MD, Kuruvilla J, Kouroukis T, Banerji V, Fraser G, Crump M, Kumar R, Chalchal HI, Salim M, Laister RC, Crocker S, Gibson SB, Toguchi M, Lyons JF, Xu H, Powers J, Sederias J, Seymour L, Hay AE.

Leuk Lymphoma. 2017 Jun;58(6):1358-1365. doi: 10.1080/10428194.2016.1239259. Epub 2016 Oct 17.

PMID:
27750483
35.

A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.

Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, Shepherd FA, Chung C, Ng R, Seymour L, Leighl NB.

Clin Lung Cancer. 2017 Jan;18(1):e41-e47. doi: 10.1016/j.cllc.2016.06.009. Epub 2016 Jul 9.

PMID:
27502323
36.

Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.

De Ruysscher D, Lueza B, Le Péchoux C, Johnson DH, O'Brien M, Murray N, Spiro S, Wang X, Takada M, Lebeau B, Blackstock W, Skarlos D, Baas P, Choy H, Price A, Seymour L, Arriagada R, Pignon JP; RTT-SCLC Collaborative Group.

Ann Oncol. 2016 Oct;27(10):1818-28. doi: 10.1093/annonc/mdw263. Epub 2016 Jul 19. Review.

37.

Beneficial Insect Attraction to Milkweeds (Asclepias speciosa, Asclepias fascicularis) in Washington State, USA.

James DG, Seymour L, Lauby G, Buckley K.

Insects. 2016 Jun 29;7(3). pii: E30. doi: 10.3390/insects7030030.

38.

RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.

Schwartz LH, Seymour L, Litière S, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, de Vries E.

Eur J Cancer. 2016 Jul;62:138-45. doi: 10.1016/j.ejca.2016.03.082. Epub 2016 May 26. Review.

39.

Clinical features of bipolar spectrum with binge eating behaviour.

McElroy SL, Crow S, Blom TJ, Cuellar-Barboza AB, Prieto ML, Veldic M, Winham SJ, Bobo WV, Geske J, Seymour LR, Mori N, Bond DJ, Biernacka JM, Frye MA.

J Affect Disord. 2016 Sep 1;201:95-8. doi: 10.1016/j.jad.2016.05.003. Epub 2016 May 6.

PMID:
27195513
40.

RECIST 1.1-Update and clarification: From the RECIST committee.

Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L.

Eur J Cancer. 2016 Jul;62:132-7. doi: 10.1016/j.ejca.2016.03.081. Epub 2016 May 14.

41.

A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.

Chen EX, Jonker DJ, Siu LL, McKeever K, Keller D, Wells J, Hagerman L, Seymour L.

Invest New Drugs. 2016 Aug;34(4):450-7. doi: 10.1007/s10637-016-0351-x. Epub 2016 Apr 13.

PMID:
27075016
42.

Under Pressure: Elevated Blood Pressure Enhances Targeting of Tumors by Oncolytic Viruses.

Seymour LW, Fisher KD.

Mol Ther. 2016 Feb;24(2):204-205. doi: 10.1038/mt.2016.19. No abstract available.

43.

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.

Ma X, Le Teuff G, Lacas B, Tsao MS, Graziano S, Pignon JP, Douillard JY, Le Chevalier T, Seymour L, Filipits M, Pirker R, Jänne PA, Shepherd FA, Brambilla E, Soria JC, Hainaut P; LACE-Bio Collaborative Group.

J Thorac Oncol. 2016 Jun;11(6):850-61. doi: 10.1016/j.jtho.2016.02.002. Epub 2016 Feb 17.

44.

A PTENtial cause for the selectivity of oncolytic viruses?

Champion BR, Fisher K, Seymour L.

Nat Immunol. 2016 Mar;17(3):225-6. doi: 10.1038/ni.3394. No abstract available.

PMID:
26882253
45.

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.

Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S, Pirker R, Douillard JY, Le Chevalier T, Filipits M, Rosell R, Kratzke R, Popper H, Soria JC, Shepherd FA, Seymour L, Tsao MS.

J Clin Oncol. 2016 Apr 10;34(11):1223-30. doi: 10.1200/JCO.2015.63.0970. Epub 2016 Feb 1.

46.

ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.

Cuffe S, Azad AK, Qiu X, Qiu X, Brhane Y, Kuang Q, Marsh S, Savas S, Chen Z, Cheng D, Leighl NB, Goss G, Laurie SA, Seymour L, Bradbury PA, Shepherd FA, Tsao MS, Chen BE, Xu W, Liu G.

Cancer Epidemiol. 2016 Apr;41:50-6. doi: 10.1016/j.canep.2015.12.012. Epub 2016 Jan 24.

PMID:
26816351
47.

Oncolytic viruses: finally delivering.

Seymour LW, Fisher KD.

Br J Cancer. 2016 Feb 16;114(4):357-61. doi: 10.1038/bjc.2015.481. Epub 2016 Jan 14. Review.

48.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Zer A, Ding K, Lee SM, Goss GD, Seymour L, Ellis PM, Hackshaw A, Bradbury PA, Han L, O'Callaghan CJ, Tsao MS, Shepherd FA.

J Thorac Oncol. 2016 Mar;11(3):312-23. doi: 10.1016/j.jtho.2015.11.010. Epub 2015 Dec 31.

49.

Evolutionarily conserved primary TNF sequences relate to its primitive functions in cell death induction.

Lu W, Chen Q, Ying S, Xia X, Yu Z, Lui Y, Tranter G, Jin B, Song C, Seymour LW, Jiang S.

J Cell Sci. 2016 Jan 1;129(1):108-20. doi: 10.1242/jcs.175463.

50.

Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.

Tedcastle A, Illingworth S, Brown A, Seymour LW, Fisher KD.

Mol Ther. 2016 Apr;24(4):796-804. doi: 10.1038/mt.2015.233. Epub 2015 Dec 28.

Supplemental Content

Loading ...
Support Center